ICCPP ODM+ Unveils Ceramic Coil Disposable and Multi-category Solution Resulted from Its Digital R&D Strategy
31.5.2022 18:58:00 EEST | Business Wire | Press release
ICCPP launched the full-range ceramic coil solution including disposable ceramic coil at Vaper Expo UK in Birmingham on May 27, 2022 -- a new category empowered by its "Digital Transformation" strategy, marking a new era in the global vape industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220528005017/en/
(Photo: Business Wire)
For the first time, ICCPP exhibited as a group and showcased its branded ODM+ solution and full-range ceramic coil solution. Adopting the Gene Tree technology, ICCPP’s ceramic coil will be integrated with the ODM+ business to promote a greater evolution in the industry. The ceramic coil, ICCPP’s first product released since it jointly launched the digital strategy with SAP and PwC, is bound to become a benchmark in the global vape industry.
Breakthrough: ceramic coil solution for disposable and multiple categories
In the vape industry, the ceramic coil technology is a key indicator of technological advancement of a company. ICCPP began to engage in the ceramic coil technology in 2019 by forming a R&D team led by "Peacock Program" talents, aiming to achieve an industry-leading level with the third or fourth generation of ceramic coil, and fully surpass the peers with the fifth or sixth generation.
Committed to becoming the leader in atomization technology, ICCPP brings a natural and pleasant vaping experience to the customers with its nanocrystalline (NC) materials and technical innovation. From thick film to thin film, from wire heating and surface heating to solid heating, ICCPP’s NC ceramic atomization technology has been constantly optimized the data model of the coil and enhancing the team's R&D strength to address the pain points in the vape coil industry. The newly launched Gene Tree thin film technology features five technical advantages, namely powder-free, improved safety, finer atomization, a longer lifespan, and an improved flavor.
As a result of the continuous endeavor of the R&D team, ICCPP recently launched the new generation of Gene Tree film technology and product applications, which, compared to the third-generation ceramic coil, has improved the flavor, increased the coil lifespan, and improved product reliability, bringing users a natural and pleasant vaping experience.
ICCPP will soon launch a disposable product equipped with the Gene Tree ceramic technology, with such features as longer-lasting flavor, more puffs, better restoration of flavor, and higher reliability, will bring revolutionary user experience, trigger a revolution in the industry, and become an industry milestone.
"Digital + technological innovation" to provide ODM + digital solution
ICCPP’s core advantages at the technical level are derived from its huge investment in scientific and technological innovation. On May 26, ICCPP announced the official launch of the "Digital Transformation Project" at its Shenzhen headquarters, becoming the world's first major company in the vape industry to cooperate with SAP and PwC. This marks that ICCPP will lead the industry into the phase of digital transformation.
The digital strategy refers to the overall digital innovation of the company integrating R&D, manufacturing, export, overseas marketing, etc. In the future, ICCPP will create an unprecedented "digital closed loop" and new digital competitiveness by creating digital R&D, digital manufacturing, digital marketing, and digital consumer experience. The mode of “digital + technological innovation” will become ICCPP’s underlying competitive advantage, including digitization + chips, digitization + fragrance, and digitization + smart manufacturing. "The company will drive development through digitalization and create new value through digitalization." Through digital transformation, the company aims to bring greater contributions to the industry and global consumers.
In order to develop ceramic coil, ICCPP quickly simulated the atomization effect by setting a data model and inputting parameters such as interface and size, so as to find the optimal configuration without sample production, thus accelerating product development and delivery. At present, ICCPP has a set of long-term plans for refillable and disposable ceramic coil products, and has reached cooperation intentions with at least 5 overseas major customers.
Mission of a leading going-out company: to empower global customers with technical innovation
ICCPP knows that customers in this era don’t need the traditional ODM anymore, but the branded ODM+. Therefore, the company has launched the new strategic partnership integrating brand positioning, user insight, product design, product development and after-sales, to guide customers to embrace new era of product customization.
Firstly, ICCPP promises to provide customers with the latest technology applications, and give them the same or even better technology as ICCPP’s own brands. Secondly, ICCPP shares all cutting-edge technologies with the entire industry chain in the strategic cooperation, including labs and institutes, automated factories, overseas user insights and global marketing services. This confidence of ICCPP comes from its rich and successful overseas experience and the ability to provide customers with one-stop services. ICCPP is committed to building two global platforms to empower customers: a truly open, Android-like vape technology platform, and a globalization platform based on years of overseas experience.
As the first strategic category after the digital upgrade, the ceramic coil solution can adapt to the full range of product lines. Emboding the industry's most advanced technologies, it is set to create a new vape category, improve user experience and bring changes to the market structure. On the one hand, ICCPP ODM+ business will undergo the digital upgrade and efficiency upgrade of the whole operation system integrating market survey, R&D, product design, order, delivery, and after-sales; on the other hand, it will establish in-depth cooperation with global customers on the ceramic coil solution. So far, ICCPP has reached cooperation intentions on this ceramic coil technology with many overseas major customers. ICCPP expects to bring more surprises to global customers and restructure the market in future.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220528005017/en/
Contact information
Media Relations: Tingkai Xu, Senior PR Manager
Mobile: 15957944779
Email: kai@voopootech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
